Paige LA, et al
It is the first triple-hormone-receptor agonist to reach advanced clinical trials, activating three distinct metabolic pathways that individually would each justify their own drug development program
However, the lack of human trials, quick degradability of liposomes and safety concerns of soy lecithin (a liposomal component) are barriers against its current use
This commercial treatment available in Slovenia was a liquid food supplement (10 mL) containing 4 g of fish collagen, 50 mg of CoQ10, 80 mg vitamin C, and 920 g of biotin administered for 12 weeks, once per day ( n = 17 placebo control
it cannot establish superiority, because differences in population, comparator, endpoint, dose, and trial length confound any direct read
doi: 10.1007/s10517-006-0323-9